<DOC>
	<DOC>NCT02780869</DOC>
	<brief_summary>The purpose of this prospective, randomized, controlled study is to evaluate the safety and efficacy of a new hemostatic device (HEMOBLAST™ Bellows) compared to a control device, absorbable gelatin sponge USP with thrombin.</brief_summary>
	<brief_title>HEMOBLAST Pivotal Clinical Investigation</brief_title>
	<detailed_description />
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Gelatin Sponge, Absorbable</mesh_term>
	<criteria>• Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic lower extremity surgery; Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation; Subject undergoing cardiothoracic surgery is not allergic to protamine; and Subject is 21 years of age or older. • Subject is undergoing a laparoscopic, thoracoscopic, or robotic surgical procedure; Subject is undergoing a neurologic surgical procedure; Subject is undergoing a spinal surgical procedure; Subject is undergoing an emergency surgical procedure; Subject is pregnant, planning on becoming pregnant during the followup period, or actively breastfeeding; Subject has a clinically significant coagulation disorder or disease, defined as a platelet count &lt; 100,000 per microliter or International Normalized Ratio &gt; 1.5 within 4 weeks of surgery; Subject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 days before surgery; Subject receiving antiplatelet medications within 5 days prior to surgery; Subject undergoing abdominal or orthopedic lower extremity surgery receiving aspirin within 7 days prior to surgery; Subject has an active or suspected infection at the surgical site; Subject has had or has planned to receive any organ transplantation; Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent; Subject has ASA classification of 5; Subject has a life expectancy of less than 3 months; Subject has a known psychiatric disorder, which in the opinion of the Principal Investigator, would preclude the subject from completing this clinical study; Subject has a documented severe congenital or acquired immunodeficiency; Subject has religious or other objections to porcine, bovine, or human components; Subject in whom the investigational or control device will be used at the site of a valve replacement or repair; Subject in whom the investigational or control device will be used at the site of a synthetic graft or patch implant; Subject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent; and Subject is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator. Intraoperative Eligibility Criteria: Subject does not have an active or suspected infection at the surgical site; Subject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to target bleeding site (TBS) identification and treatment; Subject in whom the Investigator is able to identify a TBS for which any applicable conventional means for hemostasis are ineffective or impractical; and Subject has a TBS with an SBSS score of 1, 2, or 3.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>